Phaseline

Targets › PCNA

PCNA (DNA sliding clamp PCNA): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Jan 2027.

Confers DNA tethering and processivity to DNA polymerases and other proteins. Auxiliary protein of DNA polymerase delta and epsilon, is involved in the control of DNA replication by increasing the polymerases' processivity during elongation of the leading strand. (UniProt, P12004)

Open in Phaseline: the race on PCNA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
City of Hope Medical CenterAOH1996
PCNA inhibitor
PCNAPhase 1Recurrent Acute Myeloid Leukemia; Refractory Malignant Solid NeoplasmJan 2027

Conditions

Recurrent Acute Myeloid Leukemia (1) Refractory Malignant Solid Neoplasm (1)

Modalities

other (1)

Companies

City of Hope Medical Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.